@HerreroMariajo Creo que sería más recomendable que fuera una agencia independiente al margen de la EMA que evaluara costo-efectividad de fármacos comercializados. Aquí puedes ver cómo NICE trabajaba de forma complementaria a la EMA: https://t.co/2s2mjOlj
@The_MetA_Alpha @Femi_Sorry @Otto_English @mrjamesob If I understand this correctly NICE are in place to oversee approval in the use of and to issue guidelines AFTER clinical trials by EMA or now perhaps the MHRA - a decision often based on economics (post
RT @AngryNorthernUK: @MrHickmott @AndyBurnhamGM It's probably the most obvious link in medicines. NICE has the mandate to approved EMA appr…
RT @LivUniLRiG: #AnotherOne. Check out this paper published from @LivUniLRiG and other Evidence Review Groups. https://t.co/tY4dm8MQA0
RT @LivUniLRiG: #AnotherOne. Check out this paper published from @LivUniLRiG and other Evidence Review Groups. https://t.co/tY4dm8MQA0
#AnotherOne. Check out this paper published from @LivUniLRiG and other Evidence Review Groups. https://t.co/tY4dm8MQA0
RT @PotardDechaine: Pour ceux que ça intéresse voici une analyse conduite par des membres des groupes scientifiques de NICE sur les preuves…
Pour ceux que ça intéresse voici une analyse conduite par des membres des groupes scientifiques de NICE sur les preuves d’efficacité en termes de gains de survie des nouveaux anticancéreux (cc @jdflaysakier) https://t.co/BLeS7iD8fJ (open source)
RT @ncgds: Most EMA cancer drugs licensed between 2009-2013 appraised by NICE were recommended for use in the NHS. See analysis and commen…
Most EMA cancer drugs licensed between 2009-2013 appraised by NICE were recommended for use in the NHS. However, uncertainties about cost-effectiveness and evidence quality remain. See analysis & commentary from Evidence Review Groups, including SHTAC
RT @BMJ_TAG: How do new cancer drugs make it to patients in the #NHS? Insights in @ApplHealthEcon from the great and the good in our field…
RT @BMJ_TAG: How do new cancer drugs make it to patients in the #NHS? Insights in @ApplHealthEcon from the great and the good in our field…
RT @BMJ_TAG: How do new cancer drugs make it to patients in the #NHS? Insights in @ApplHealthEcon from the great and the good in our field…
How do new cancer drugs make it to patients in the #NHS? Insights in @ApplHealthEcon from the great and the good in our field about the current status of the @EMA_News and @NICEcomms appraisal processes https://t.co/wXgm6vTPkP #cancer #HTA
Most EMA cancer drugs licensed between 2009-2013 appraised by NICE were recommended for use in the NHS. However, uncertainties about cost-effectiveness and evidence quality remain. See analysis & commentary from Evidence Review Groups, including SHTAC
#HealthEconJA EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties https://t.co/nhzNkeb864